Metastatic melanoma in a young woman treated with TNF-alpha inhibitor for Psoriatic arthritis: A case report

Current Drug Safety

Volumn 6, Issue 4, 2011, Pages 275-276

  Marasini, Bianca ^a,b   Cozzaglio, Luca ^a   Belloli, Laura ^a   Massarotti, Marco ^a   Ughi, Nicola ^a   Pedrazzoli, Paolo ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Adalimumab; Melanoma; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACHILLES TENDON; ADULT; ARTICLE; BONE RADIOGRAPHY; CANCER SURGERY; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; HUMAN; LYMPH NODE DISSECTION; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SYNOVITIS; TREATMENT DURATION;

EID: 83455220142     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611798280915     Document Type: Article

References (18)

1. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility, Oncologist 2006; 11: 397-408.
2. Sheppard J, Raza K, Buckley CD. Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology (Oxford) 2007; 46: 1622-23.
3. Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008; 58: 82-7.
4. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64: 1035-50.
5. Geborek P, Bladstrom A, Turesson C, et al. Tumor necrosis factor blockers do not increase overall tumor risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.
6. Nannini C, Cantini F, Niccoli L, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor α therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 2009; 61: 801-12.
7. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60: 3180-9.
8. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006; 65: 617-22.
9. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 1991; 18: 809-14.
10. US Food and Drug Administration website. Arthritis Drugs Advisory Committee. Safety update on TNF-alpha antagonists. Available at: www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm. Accessed January 12, 2010.
11. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 2007; 56: 2886-95.
12. Marie C, Delesalle F, Carpentier O, Lequint P, Delaporte E, Thomas P. Multiple basal cell carcinomas after etanercept treatmeny for psoriasis. Ann Dermatol Venereol 2009; 136: 355-59.
13. Dreyer L, Mellemkjaer L, Hetland ML. Cancer in arthritis patients after anti-tumour necrosis factor therapy. Ugeskr Laeger 2009; 171: 506-11.
14. Fulchiero GJ, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007; 56: S65-S67.
15. Kowalzick L, Eickenscheidt L, Komar M, Schaarschmidt E. Long term treatment of psoriasis with TNF-alpha antagonists: Occurrence of malignant melanoma. Hautarzt 2009; 60: 655-57.
16. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005, 153: 486-97.
17. Brauchli YB, jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer; an inception cohort study with a nested casecontrol analysis. J Invest Dermatol 2009; 129: 2604-12.
18. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68: 1100-4.